ImmunoPrecise Antibodies Ltd. (IPA.V)

7.00 +0.35 (+5.26%) At close: 03:57PM EDT

ImmunoPrecise Antibodies Ltd.

3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada

https://www.ipatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 85

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jennifer Lynne Bath Ph.D.	CEO, Pres & Non-Independent Director	1.05M	N/A	N/A
Brad Mcconnell	Chief Financial Officer	N/A	N/A	N/A
Mr. David E. Orton	Chief Operating Officer	N/A	N/A	N/A
Dr. Ilse Roodink	Chief Scientific Officer	N/A	N/A	N/A
Ms. Carla Dahl	VP of Marketing	N/A	N/A	N/A
Dr. Barry Neil Duplantis	VP of Client Relations	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Corporate Governance

ImmunoPrecise Antibodies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.